Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
50561 in mild to moderate Alzheimer's disease
NCT05811442Phase 2Completed
- Sponsor
- Beijing Joekai Biotechnology
- Start
- Apr 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JK 50561 in Alzheimer's disease (AD) (3 arms), sponsored by Beijing Joekai Biotechnology. Primary endpoint: Alzheimer's Disease Assessment Scale-Cognition 13 at 24 weeks. Started Apr 2023; status: completed.
02
Drugs
JK 50561
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05811442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05811442.